ArticleMedicine2026
A Mendelian randomization study reveals TNF-β as a potential protective factor against sarcopenia.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Sarcopenia, defined by the loss of muscle mass and strength, significantly impacts the elderly and is linked to chronic inflammation. The exact causal relationship between circulating inflammatory factors and sarcopenia is not yet clear. We employed a 2-sample Mendelian randomization analysis using 91 circulating inflammatory factors as exposures and 4 sarcopenia traits as outcomes to explore potential causality. Our analysis confirmed a significant causal association between circulating inflammatory factors and sarcopenia. Specifically, tumor necrosis factor-beta was significantly associated with all sarcopenia traits (appendicular lean mass: P < .001, odds ratio [OR] = 1.023; left grip strength: P < .001, OR = 1.010; right grip strength: P = .001, OR = 1.008; walking pace: P = .017, OR = 1.004), supported by Bonferroni correction and multiple sensitivity analyses. Tumor necrosis factor-beta has emerged as a critical protective factor for sarcopenia, suggesting that targeting its levels may influence treatment approaches. This study emphasized the role of inflammatory pathways in sarcopenia and demonstrated the utility of Mendelian randomization in identifying these associations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.